Engaging hepatitis C infected patients in cost‐effectiveness analyses: A literature review

T. Joseph Mattingly, Eleanor M. Perfetto, Sophia L. Johnson – 23 August 2017 – Cost‐effectiveness analyses (CEAs) of hepatitis C virus (HCV) treatment strategies have become common, but few appear to include patient engagement or the patient perspective. The objectives of the current study were to (1) identify published HCV CEA studies that include patient input and (2) derive insights on patient‐informed variable and outcome selection to build a framework for future economic analyses of HCV.

Self‐assembled liver organoids recapitulate hepatobiliary organogenesis in vitro

Dipen Vyas, Pedro M. Baptista, Matthew Brovold, Emma Moran, Brandon Gaston, Chris Booth, Michael Samuel, Anthony Atala, Shay Soker – 23 August 2017 – Several three‐dimensional cell culture systems are currently available to create liver organoids. In gneral, these systems display better physiologic and metabolic aspects of intact liver tissue compared with two‐dimensional culture systems. However, none reliably mimic human liver development, including parallel formation of hepatocyte and cholangiocyte anatomical structures.

Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection

Nancy Reau, Michael N. Robertson, Hwa‐Ping Feng, Luzelena Caro, Wendy W. Yeh, Bach‐Yen T. Nguyen, Janice Wahl, Eliav Barr, Peggy Hwang, Stephanie O. Klopfer – 22 August 2017 – Concomitant proton pump inhibitor (PPI) use reduces plasma concentrations of certain nonstructural protein 5A inhibitors, which are key components of modern hepatitis C infection (HCV) treatments. These reduced concentrations may decrease efficacy, leading to challenging treatment failures due to the development of resistance‐associated substitutions.

Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B

Xupeng Hong, Elena S. Kim, Haitao Guo – 18 August 2017 – Hepatitis B virus (HBV) infection represents a significant public health burden worldwide. Although current therapeutics manage to control the disease progression, lifelong treatment and surveillance are required because drug resistance develops during treatment and reactivations frequently occur following medication cessation. Thus, the occurrence of hepatocellular carcinoma is decreased, but not eliminated.

Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B

Xupeng Hong, Elena S. Kim, Haitao Guo – 18 August 2017 – Hepatitis B virus (HBV) infection represents a significant public health burden worldwide. Although current therapeutics manage to control the disease progression, lifelong treatment and surveillance are required because drug resistance develops during treatment and reactivations frequently occur following medication cessation. Thus, the occurrence of hepatocellular carcinoma is decreased, but not eliminated.

A microRNA‐7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib‐resistant cells in human hepatocellular carcinoma

Tasnuva D. Kabir, Clarissa Ganda, Rikki M. Brown, Dianne J. Beveridge, Kirsty L. Richardson, Vishal Chaturvedi, Patrick Candy, Michael Epis, Larissa Wintle, Felicity Kalinowski, Christina Kopp, Lisa M. Stuart, George C. Yeoh, Jacob George, Peter J. Leedman – 18 August 2017 – Sorafenib remains the only approved drug for treating patients with advanced hepatocellular carcinoma (HCC). However, the therapeutic effect of sorafenib is transient, and patients invariably develop sorafenib resistance (SR).

Subscribe to